Healthcare provider profile · identity verified

Lester J. Kobylak, M.D.

Internal Medicine · DETROIT, MI · NPI 1811065360

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	528	169
Amlodipine Besylate	Amlodipine Besylate	380	113
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	291	38
Metformin Hcl	Metformin Hcl	233	71
Losartan Potassium	Losartan Potassium	201	75
Lisinopril	Lisinopril	195	50
Nifedipine Er	Nifedipine	190	52
Simvastatin	Simvastatin	170	49
Hydrochlorothiazide	Hydrochlorothiazide	161	38
Gabapentin	Gabapentin	158	35
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	150	46
Eliquis	Apixaban	138	38
Levothyroxine Sodium	Levothyroxine Sodium	136	42
Fluticasone Propionate	Fluticasone Propionate	135	52
Ozempic	Semaglutide	135	28
Omeprazole	Omeprazole	134	35
Pantoprazole Sodium	Pantoprazole Sodium	131	43
Tamsulosin Hcl	Tamsulosin Hcl	119	41
Metoprolol Succinate	Metoprolol Succinate	111	36
Albuterol Sulfate Hfa	Albuterol Sulfate	110	38
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	89	89
Acetaminophen-Codeine	Acetaminophen With Codeine	86	20
Carvedilol	Carvedilol	78	23
Furosemide	Furosemide	78	30
Jardiance	Empagliflozin	78	25
Triamcinolone Acetonide	Triamcinolone Acetonide	76	37
Allopurinol	Allopurinol	73	23
Famotidine	Famotidine	73	18
Metoprolol Tartrate	Metoprolol Tartrate	68	20
Ibuprofen	Ibuprofen	67	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	65	23
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	63	19
Alprazolam	Alprazolam	62	15
Prednisone	Prednisone	60	46
Benazepril Hcl	Benazepril Hcl	58	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	16
Naproxen	Naproxen	56	25
Spironolactone	Spironolactone	55	17
Rosuvastatin Calcium	Rosuvastatin Calcium	52	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	18
Ventolin Hfa	Albuterol Sulfate	49	20
Alendronate Sodium	Alendronate Sodium	47	15
Hydrocortisone	Hydrocortisone	46	12
Pregabalin	Pregabalin	45	suppressed
Methocarbamol	Methocarbamol	42	17
Hydralazine Hcl	Hydralazine Hcl	41	12
Pravastatin Sodium	Pravastatin Sodium	40	12
Chlorthalidone	Chlorthalidone	38	12
Mounjaro	Tirzepatide	36	suppressed
Atenolol	Atenolol	35	suppressed
Clopidogrel	Clopidogrel Bisulfate	35	15
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	34	suppressed
Xarelto	Rivaroxaban	34	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	suppressed
Warfarin Sodium	Warfarin Sodium	33	12
Shingrix	Varicella-Zoster Ge/As01b/Pf	31	28
Ezetimibe	Ezetimibe	30	suppressed
Potassium Chloride	Potassium Chloride	30	13
Januvia	Sitagliptin Phosphate	29	suppressed
Metformin Hcl Er	Metformin Hcl	29	11
Tizanidine Hcl	Tizanidine Hcl	29	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	26	suppressed
Finasteride	Finasteride	26	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	25	suppressed
Diazepam	Diazepam	24	suppressed
Levetiracetam	Levetiracetam	24	suppressed
Montelukast Sodium	Montelukast Sodium	24	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Lorazepam	Lorazepam	23	suppressed
Methimazole	Methimazole	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Baclofen	Baclofen	19	suppressed
Trazodone Hcl	Trazodone Hcl	19	suppressed
Clotrimazole	Clotrimazole	18	suppressed
Labetalol Hcl	Labetalol Hcl	18	suppressed
Sildenafil Citrate	Sildenafil Citrate	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	11
Alcohol Swabs	Alcohol Antiseptic Pads	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Risedronate Sodium	Risedronate Sodium	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Entacapone	Entacapone	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Sertraline Hcl	Sertraline Hcl	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Ammonium Lactate	Ammonium Lactate	11	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	11	11
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error